티디에스팜

464280KOSDAQ의약품 제조업

64.3 / 100

Reference Date: 2026-04-13

Financial Score28.5 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Declined 11.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

TDS Pharm specializes in the development and manufacturing of transdermal drug delivery systems (TDDS), holding a leading position in the Korean market with key products like Cataplasma and Plaster. The company aims to grow into a global pharmaceutical firm by expanding its portfolio to include patches targeting dementia, asthma, nicotine addiction, and other therapeutic areas.

Number of Employees

111people

Average Salary

32.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.96Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

1.09Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

10.52Industry Average 4.427.0Point

2.4x industry avg (excellent)

Debt Ratio

0.38Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2024~20254.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.4% (1-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.9% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.3% (declining, 2yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
티디에스팜, 자본준비금 감액 및 이익잉여금 전입 추진
티디에스팜이 자본준비금 감액 및 이익잉여금 전입 안건을 정기주주총회에 상정하여 향후 안정적인 주주환원 정책 기반을 마련할 계획입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 8,470Won52-week high 12,84052-week low 8,000

1-month return1.0Point

1m -11.77% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]정기주주총회결과2026-03-30
Neutral정기주주총회결과2026-03-25
Neutral[기재정정]주주총회소집공고2026-03-23
Neutral사업보고서 (2025.12)2026-03-17
Neutral감사보고서제출2026-03-17